PURPOSE: Treatment of acute myeloid leukemia (AML) is associated with substantial adverse effects, including neutropenia and infection. Viridans streptococci (VS) are a primary cause of infection and pneumonia in patients with neutropenia. The authors determined the incidence, clinical features, and complications of VS sepsis in children receiving chemotherapy for AML. METHODS: The authors retrospectively reviewed the records of 172 patients treated on their institutional protocols AML91 (n = 95) and AML97 (n = 77) and identified 36 patients who had VS sepsis. RESULTS: The 1-year cumulative incidence of VS sepsis was significantly higher in AML97 than in AML91. Patients with favorable cytogenetic features (ie, t(9;11), t(8;21), or inv(16)) had a significantly higher incidence of infection than did other patients. VS sepsis developed at various times after chemotherapy was initiated, and patients remained febrile for a median of 15 days. Twelve patients (33%) experienced hypotension, 10 (28%) acute respiratory distress syndrome, and 6 (17%) fungal infection. Twenty-three patients (64%) required intensive care, 21 (58%), oxygen therapy, and 7 (19%), vasopressor medications. One patient died of pulmonary aspergillosis after VS sepsis. The 3-year cumulative incidence of aspergillosis was higher in patients with VS sepsis than in those without. CONCLUSIONS: Although antibiotic therapy rapidly resolved VS sepsis, complications associated with this infection remained life-threatening in children receiving chemotherapy for AML.
PURPOSE: Treatment of acute myeloid leukemia (AML) is associated with substantial adverse effects, including neutropenia and infection. Viridans streptococci (VS) are a primary cause of infection and pneumonia in patients with neutropenia. The authors determined the incidence, clinical features, and complications of VS sepsis in children receiving chemotherapy for AML. METHODS: The authors retrospectively reviewed the records of 172 patients treated on their institutional protocols AML91 (n = 95) and AML97 (n = 77) and identified 36 patients who had VS sepsis. RESULTS: The 1-year cumulative incidence of VS sepsis was significantly higher in AML97 than in AML91. Patients with favorable cytogenetic features (ie, t(9;11), t(8;21), or inv(16)) had a significantly higher incidence of infection than did other patients. VS sepsis developed at various times after chemotherapy was initiated, and patients remained febrile for a median of 15 days. Twelve patients (33%) experienced hypotension, 10 (28%) acute respiratory distress syndrome, and 6 (17%) fungal infection. Twenty-three patients (64%) required intensive care, 21 (58%), oxygen therapy, and 7 (19%), vasopressor medications. One patient died of pulmonary aspergillosis after VS sepsis. The 3-year cumulative incidence of aspergillosis was higher in patients with VS sepsis than in those without. CONCLUSIONS: Although antibiotic therapy rapidly resolved VS sepsis, complications associated with this infection remained life-threatening in children receiving chemotherapy for AML.
Authors: Anne Reilly; Leslie S Kersun; Eline Luning Prak; Jean Boyer; Kenyetta McDonald; Abbas F Jawad; Kathleen E Sullivan Journal: J Pediatr Hematol Oncol Date: 2013-01 Impact factor: 1.289
Authors: L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer Journal: Blood Rev Date: 2014-09-30 Impact factor: 8.250
Authors: Romy E Van Weelderen; Kim Klein; Bianca F Goemans; Wim J E Tissing; Tom F W Wolfs; Gertjan J L Kaspers Journal: Cancers (Basel) Date: 2022-06-28 Impact factor: 6.575
Authors: Hana Hakim; Patricia M Flynn; Katherine M Knapp; Deo Kumar Srivastava; Aditya H Gaur Journal: J Pediatr Hematol Oncol Date: 2009-09 Impact factor: 1.289
Authors: Naima A Al-Mulla; Saad J Taj-Aldeen; Sittana El Shafie; Mohammed Janahi; Abdullah A Al-Nasser; Prem Chandra Journal: Infect Drug Resist Date: 2014-11-06 Impact factor: 4.003
Authors: Maryke J Nielsen; Sarah Claxton; Barry Pizer; Steven Lane; Richard P D Cooke; Stéphane Paulus; Enitan D Carrol Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889